Universität zu Köln

Van Gool, Stefaan W., Makalowski, Jennifer, Fiore, Simon, Sprenger, Tobias, Prix, Lothar, Schirrmacher, Volker ORCID: 0000-0003-1253-9145 and Stuecker, Wilfried (2021). Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged. Cancers, 13 (1). BASEL: MDPI. ISSN 2072-6694

Full text not available from this repository.

Abstract

Simple Summary: Although multiple meta-analyses on active specific immunotherapy treatment for glioblastoma multiforme (GBM) have demonstrated a significant prolongation of overall survival, no single research group has succeeded in demonstrating the efficacy of this type of treatment in a prospective, double-blind, placebo-controlled, randomized clinical trial. In this paper, we explain how the complexity of the tumor biology and tumor-host interactions make proper stratification of a control group impossible. The individualized characteristics of advanced therapy medicinal products for immunotherapy contribute to heterogeneity within an experimental group. The dynamics of each tumor and in each patient aggravate comparative stable patient groups. Finally, combinations of immunotherapy strategies should be integrated with first-line treatment. We illustrate the complexity of a combined first-line treatment with individualized multimodal immunotherapy in a group of 70 adults with GBM and demonstrate that the integration of immunogenic cell death treatment within maintenance chemotherapy followed by dendritic cell vaccines and maintenance immunotherapy might provide a step towards improving the overall survival rate of GBM patients. Immunotherapies represent a promising strategy for glioblastoma multiforme (GBM) treatment. Different immunotherapies include the use of checkpoint inhibitors, adoptive cell therapies such as chimeric antigen receptor (CAR) T cells, and vaccines such as dendritic cell vaccines. Antibodies have also been used as toxin or radioactive particle delivery vehicles to eliminate target cells in the treatment of GBM. Oncolytic viral therapy and other immunogenic cell death-inducing treatments bridge the antitumor strategy with immunization and installation of immune control over the disease. These strategies should be included in the standard treatment protocol for GBM. Some immunotherapies are individualized in terms of the medicinal product, the immune target, and the immune tumor-host contact. Current individualized immunotherapy strategies focus on combinations of approaches. Standardization appears to be impossible in the face of complex controlled trial designs. To define appropriate control groups, stratification according to the Recursive Partitioning Analysis classification, MGMT promotor methylation, epigenetic GBM sub-typing, tumor microenvironment, systemic immune functioning before and after radiochemotherapy, and the need for/type of symptom-relieving drugs is required. Moreover, maintenance of a fixed treatment protocol for a dynamic, deadly cancer disease in a permanently changing tumor-host immune context might be inappropriate. This complexity is illustrated using our own data on individualized multimodal immunotherapies for GBM. Individualized medicines, including multimodal immunotherapies, are a rational and optimal yet also flexible approach to induce long-term tumor control. However, innovative methods are needed to assess the efficacy of complex individualized treatments and implement them more quickly into the general health system.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Van Gool, Stefaan W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Makalowski, Jennifer UNSPECIFIED UNSPECIFIED UNSPECIFIED Fiore, Simon UNSPECIFIED UNSPECIFIED UNSPECIFIED Sprenger, Tobias UNSPECIFIED UNSPECIFIED UNSPECIFIED Prix, Lothar UNSPECIFIED UNSPECIFIED UNSPECIFIED Schirrmacher, Volker UNSPECIFIED orcid.org/0000-0003-1253-9145 UNSPECIFIED Stuecker, Wilfried UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-568753
DOI:	10.3390/cancers13010032
Journal or Publication Title:	Cancers
Volume:	13
Number:	1
Date:	2021
Publisher:	MDPI
Place of Publication:	BASEL
ISSN:	2072-6694
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DENDRITIC CELL VACCINATION; NEWLY-DIAGNOSED GLIOBLASTOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; RECURRENT MALIGNANT GLIOMA; CENTRAL-NERVOUS-SYSTEM; LONG-TERM SURVIVAL; HIGH-GRADE GLIOMAS; CYTOTOXIC T-CELLS; PHASE-I TRIAL; TUMOR-LYSATE Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/56875